Galapagos NV (GLPG)
Fuera de horario:
Galapagos NV
Generaal De Wittelaan L11 A3
Mechelen 2800
Belgium
32 1 534 29 00
https://www.glpg.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 1,123
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Paulus A. Stoffels M.D., Ph.D. | CEO, Chairman, Interim Head of R&D | 1.35M | N/D | 1962 |
| Mr. Thad Huston | Executive VP, CFO & COO | N/D | N/D | 1971 |
| Ms. Sofie Van Gijsel | Head of Investor Relations | N/D | N/D | N/D |
| Ms. Valeria Cnossen | Executive VP & General Counsel | N/D | N/D | 1974 |
| Marieke Vermeersch | Head of Corporate Communication | N/D | N/D | N/D |
| Ms. Annelies Missotten | Executive VP & Chief Human Resources Officer | N/D | N/D | 1973 |
| Ms. Ellen Van Der Aar | Head of Development | N/D | N/D | N/D |
| Mr. Philippe Alen M.B.A., Ph.D., Pharm.D. | Senior VP & Head of Business Development | N/D | N/D | N/D |
| Mr. Dirk De Naeyer | Head of Development Operations | N/D | N/D | N/D |
| Ms. Alice Dietrich | Head of Medical Affairs | N/D | N/D | N/D |
Descripción
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.
Gestión corporativa
La calificación ISS Governance QuickScore de Galapagos NV a partir del 1 de abril de 2024 es 7. Las puntuaciones principales son Auditoría: 7; Junta: 4; Derechos del accionista: 4; Compensación: 10.
